Parnell, a veterinary pharmaceutical company, announced that it has acquired Noble Pharma, a U.S.-based pharmaceutical manufacturer, under a Securities Purchase Agreement dated November 26, 2025.
The acquisition adds an FDA- and DEA-accredited manufacturing facility to Parnell’s operations, strengthening its presence in the United States and supporting its long-term strategy to deliver high-quality products and reliable supply to customers and distribution partners. Noble Pharma’s capabilities enhance Parnell’s manufacturing footprint, improve supply continuity, and enable growth across its expanding product portfolio.
Noble Pharma, located in Menomonie, Wisconsin, produces a wide range of pharmaceutical formats, including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.
Parnell said the transaction positions the company to scale production, accelerate innovation, and better serve its growing customer base across the U.S. market and internationally. The company currently develops, manufactures, and commercializes animal health solutions for companion and production animals in 10 countries.
KEY QUOTE:
“Completing this acquisition marks an important milestone for Parnell. Noble Pharma’s operational excellence and established U.S. manufacturing footprint perfectly complement our mission to provide consistent supply, superior quality, and exceptional service to our partners and customers.”
Brad McCarthy, Chief Executive Officer of Parnell
